Qualcomm (QCOM) – Broadcom (AVGO) battle has off late witnessed some tense and nail-biting moments. The latest twist in this battle took place when Broadcom announced that chip maker Qualcomm had secretly approached the U.S. national security panel early this year, requesting them to investigate this deal. The U.S. government has responded to this by asking Qualcomm to postpone the company’s March 6 annual shareholder meeting by a month.
The upcoming annual shareholder meeting was an event that had all the industry watchers attention, as it would be decided whether the six nominees recommended by Singapore-based Broadcom would gain control over Qualcomm. If it did happen, it was a clear message that the shareholders support the hostile takeover by Broadcom. But this has been intervened by Qualcomm’s latest approach to the Committee on Foreign Investment in the United States (CFIUS).
CFIUS is a committee that reviews the foreign acquisitions of U.S. firms to determine whether an acquisition will result in a threat to the national security. Though the CFIUS cannot block a deal, it can impose certain changes.
Broadcom, which recently cut its offer price for Qualcomm by 4% to $117 billion, was under the impression that the only barrier in its way was Qualcomm’s acquisition of NXP Semiconductors. But now the entire Broadcom-Qualcomm deal has fallen under the security scanner.
This latest plot that unfolded came as a surprise to Broadcom, who openly showed its disappointment, stating Qualcomm had never made any reference to submitting a voluntary notice to CFIUS during the earlier interactions.
Broadcom, which earlier revealed its commitment to redomicile to the U.S., is expected to get all the required approvals by the end of its second fiscal quarter this year i.e. May 6, 2018. Considering this, Broadcom argues that this takeover does not require to be reviewed by the CFIUS.
Despite these hurdles, Broadcom never gave any sign of giving up and is determined to acquire Qualcomm, which is making every possible move to stay independent. The determined Broadcom says it understands the importance of CFIUS and will offer its complete co-operation towards the committee.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on